Management of bone disease in multiple myeloma

Evangelos Terpos, James Berenson, Noopur Raje, G. David Roodman

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.

Original languageEnglish
Pages (from-to)113-125
Number of pages13
JournalExpert Review of Hematology
Volume7
Issue number1
DOIs
StatePublished - Feb 2014

Fingerprint

zoledronic acid
Bone Diseases
Multiple Myeloma
pamidronate
Diphosphonates
Clodronic Acid
Spontaneous Fractures
Spinal Cord Compression
Radiotherapy
Morbidity
Pain
Survival
Mortality
Therapeutics

Keywords

  • activin-A
  • bisphosphonates
  • bone disease
  • denosumab
  • RANKL
  • sclerostin
  • sotatercept
  • Wnt pathway

ASJC Scopus subject areas

  • Hematology

Cite this

Management of bone disease in multiple myeloma. / Terpos, Evangelos; Berenson, James; Raje, Noopur; Roodman, G. David.

In: Expert Review of Hematology, Vol. 7, No. 1, 02.2014, p. 113-125.

Research output: Contribution to journalArticle

Terpos, Evangelos ; Berenson, James ; Raje, Noopur ; Roodman, G. David. / Management of bone disease in multiple myeloma. In: Expert Review of Hematology. 2014 ; Vol. 7, No. 1. pp. 113-125.
@article{08540083c0144ae298ccf1c795504b2e,
title = "Management of bone disease in multiple myeloma",
abstract = "Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.",
keywords = "activin-A, bisphosphonates, bone disease, denosumab, RANKL, sclerostin, sotatercept, Wnt pathway",
author = "Evangelos Terpos and James Berenson and Noopur Raje and Roodman, {G. David}",
year = "2014",
month = "2",
doi = "10.1586/17474086.2013.874943",
language = "English",
volume = "7",
pages = "113--125",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Management of bone disease in multiple myeloma

AU - Terpos, Evangelos

AU - Berenson, James

AU - Raje, Noopur

AU - Roodman, G. David

PY - 2014/2

Y1 - 2014/2

N2 - Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.

AB - Osteolytic bone disease is the most common complication of multiple myeloma, resulting in skeletal complications that cause significant morbidity and mortality. Currently, bisphosphonates (BPs) are the mainstay for the treatment of myeloma bone disease. Zoledronic acid which has been found to be superior to clodronate, both in terms of reduction of skeletal-related events (SREs) and survival, and pamidronate are used for the management of myeloma-related bone disease. Patients with active disease (not in CR or VGPR) should receive BPs (especially zoledronic acid) even after two years of administration. Radiotherapy and surgical interventions can also be used for specific conditions, such as pathological fractures, spinal cord compression or uncontrolled pain. The better understanding of the biology of myeloma bone disease has led to the production of several novel agents, such as denosumab (targeting RANKL), sotatercept (activin-A antagonist) and romosozumab (targeting sclerostin) that appear very promising and have entered to clinical development.

KW - activin-A

KW - bisphosphonates

KW - bone disease

KW - denosumab

KW - RANKL

KW - sclerostin

KW - sotatercept

KW - Wnt pathway

UR - http://www.scopus.com/inward/record.url?scp=84893301626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893301626&partnerID=8YFLogxK

U2 - 10.1586/17474086.2013.874943

DO - 10.1586/17474086.2013.874943

M3 - Article

C2 - 24433088

AN - SCOPUS:84893301626

VL - 7

SP - 113

EP - 125

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 1

ER -